{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T19:47:47Z","timestamp":1767383267262,"version":"3.41.2"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p>A meta-analysis was conducted to assess the benefits and risks of aspirin for the primary prevention of cardiovascular disease and all-cause mortality events in adults with diabetes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>An extensive and systematic search was conducted in MEDLINE (via PubMed), Cinahl (via Ebsco), Scopus, and Web of Sciences from 1988 to December 2020.\u00a0A detailed literature search was conducted using aspirin, cardiovascular disease (CVD), diabetes, and efficacy to identify trials of patients with diabetes who received aspirin for primary prevention of CVD. Demographic details with the primary outcome of events and bleeding outcomes were analyzed. The Cochrane Collaboration\u2019s risk of bias tool was used to assess the methodological quality of the included studies. Random-effects meta-analysis was used to calculate the pooled odds ratio for outcomes of cardiovascular events, death, and adverse events.<\/jats:p><\/jats:sec><jats:sec><jats:title>Findings<\/jats:title><jats:p>A total of 8 studies were included with 32,024 patients with diabetes; 16,001 allocated to aspirin, and 16,023 allocated to the control group. There was no difference between aspirin and control groups with respect to all-cause mortality, cardiovascular mortality, or bleeding events. However, MACE was significantly lower in the aspirin group.<\/jats:p><\/jats:sec><jats:sec><jats:title>Implications<\/jats:title><jats:p>Although aspirin has no significant risk on primary endpoints of cardiovascular events and bleeding outcomes in patients with diabetes compared to control, major adverse cardiovascular events (MACE) were significantly lower in the aspirin group. Further research on the use of aspirin alone or in combination with other antiplatelet drugs is required in patients with diabetes to supplement currently available research. <\/jats:p><\/jats:sec><jats:sec><jats:title>Systematic Review Registration<\/jats:title><jats:p>identifier [XU#\/IRB\/2020\/1005].<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2021.741374","type":"journal-article","created":{"date-parts":[[2021,9,4]],"date-time":"2021-09-04T01:38:04Z","timestamp":1630719484000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Benefits and Risks Associated With Aspirin Use in Patients With Diabetes for the Primary Prevention of Cardiovascular Events and Mortality: A Meta-Analysis"],"prefix":"10.3389","volume":"12","author":[{"given":"Hua","family":"Ma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing","family":"Gu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huining","family":"Niu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaohua","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,9,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw106","article-title":"ESC Scientific Document Group. 2016 European Guidelines on Cardiovascular Disease Prevention in Clinical Practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by Representatives of 10 Societies and by Invited Experts) Developed With the Special Contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR)","volume":"37","author":"Piepoli","year":"2016","journal-title":"Eur Heart J"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2008.02640.x","article-title":"Is Diabetes a Coronary Risk Equivalent? Systematic Review and Meta-Analysis","volume":"26","author":"Bulugahapitiya","year":"2009","journal-title":"Diabetes Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.96.8.2751","article-title":"Aspirin as a Therapeutic Agent in Cardiovascular Disease: A Statement for Healthcare Professionals From the American Heart Association","volume":"96","author":"Hennekens","year":"1997","journal-title":"Circulation"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.amepre.2005.08.042","article-title":"Aspirin Use Among U.S. Adults: Behavioral Risk Factor Surveillance System","volume":"30","author":"Ajani","year":"2006","journal-title":"Am J Prev Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3121\/cmr.2013.1197","article-title":"The Role of Aspirin in the Prevention of Cardiovascular Disease","volume":"12","author":"Ittaman","year":"2014","journal-title":"Clin Med Res"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804988","article-title":"Effects of Aspirin for Primary Prevention in Persons With Diabetes Mellitus. The ASCEND Study Collaborative Group","volume":"379","author":"Bowman","year":"2018","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1803955","article-title":"ASPREE Investigator Group. Effect of Aspirin on All-Cause Mortality in the Healthy Elderly","volume":"379","author":"McNeil","year":"2018","journal-title":"N Engl J Med"},{"key":"B8","article-title":"Aspirin Effects on Mortality and Morbidity in Patients With Diabetes Mellitus","volume":"268","year":"1992","journal-title":"JAMA"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2008.623","article-title":"Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial Investigators. Low-Dose Aspirin for Primary Prevention of Atherosclerotic Events in Patients With Type 2 Diabetes. A Randomized Controlled Trial","volume":"300","author":"Ogawa","year":"2008","journal-title":"JAMA"},{"key":"B10","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.ahj.2009.11.030","article-title":"Rationale, Design, and Baseline Data of the Japanese Primary Prevention Project (PPP)-A Randomized, Open-Label, Controlled Trial of Aspirin Versus No Aspirin in Patients With Multiple Risk Factors for Vascular Events","volume":"159","author":"Teramoto","year":"2010","journal-title":"Am Heart J"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1136\/BMJ.a1840","article-title":"The Prevention of Progression of Arterial Disease and Diabetes (POPADAD) Trial: Factorial Randomised Placebo-Controlled Trial of Aspirin and Antioxidants in Patients With Diabetes and Asymptomatic Peripheral Arterial Disease","volume":"337","author":"Belch","year":"2008","journal-title":"BMJ"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.26.12.3264","article-title":"Primary Prevention of Cardiovascular Events With Low-Dose Aspirin and Vitamin E in Type 2 Diabetic Patients. Results of the Primary Prevention Project (PPP) Trial","volume":"26","author":"Sacco","year":"2003","journal-title":"Diabetes Care"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050613","article-title":"A Randomized Trial of Low-Dose Aspirin in the Primary Prevention of Cardiovascular Disease in Women","volume":"352","author":"Ridker","year":"2005","journal-title":"N Eng J Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-136-2-200201150-00015","article-title":"Aspirin for the Primary Prevention of Cardiovascular Events: Recommendation and Rationale","volume":"136","author":"Preventive Services Task Force","year":"2002","journal-title":"Ann Intern Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehy813","article-title":"Efficacy and Safety of Aspirin for Primary Prevention of Cardiovascular Events: A Meta-Analysis and Trial Sequential Analysis of Randomized Controlled Trials","volume":"40","author":"Mahmoud","year":"2019","journal-title":"Eur Heart J"},{"key":"B16","article-title":"American Diabetes Association","volume":"26","author":"Colwell","year":"2003","journal-title":"Aspirin Ther diabetes Diabetes Care"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198907203210301","article-title":"Steering Committee of the Physicians\u2019 Health Study Research Group. Final Report on the Aspirin Component of the Ongoing Physicians\u2019 Health Study","volume":"321","year":"1989","journal-title":"N Engl J Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)11475-1","article-title":"The Medical Research Council\u2019s General Practice Research Framework. Thrombosis Prevention Trial: Randomised Trial of Low-Intensity Oral Anticoagulation With Warfarin and Low-Dose Aspirin in the Primary Prevention of Ischaemic Heart Disease in Men at Increased Risk","volume":"351","year":"1998","journal-title":"Lancet"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)04311-6","article-title":"Effects of Intensive Blood-Pressure Lowering and Low-Dose Aspirin in Patients With Hypertension: Principal Results of the Hypertension Optimal Treatment (HOT) Randomised Trial","volume":"351","author":"Hansson","year":"1998","journal-title":"Lancet"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2010.04.003","article-title":"Aspirin for Primary Prevention of Cardiovascular Events in People With Diabetes","volume":"55","author":"Pignone","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s Tool for Assessing Risk of Bias in Randomised Trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring Inconsistency in Meta-Analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.106.658948","article-title":"Increasing Cardiovascular Disease Burden Due to Diabetes Mellitus: The Framingham Heart Study","volume":"115","author":"Fox","year":"2007","journal-title":"Circulation"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.320.7244.1262","article-title":"ABC of Arterial and Vascular Disease: Secondary Prevention of Peripheral Vascular Disease","volume":"320","author":"Tierney","year":"2000","journal-title":"BMJ"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.163.8.884","article-title":"Critical Issues in Peripheral Arterial Disease Detection and Management","volume":"163","author":"Belch","year":"2003","journal-title":"A call to action Arch Intern Med"},{"key":"B26","unstructured":"Diagnosis and Management of Peripheral Arterial Disease: A National Clinical Guideline2006"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000091257.27563.32","article-title":"Diabetes and Vascular Disease: Pathophysiology, Clinical Consequences, and Medical Therapy: Part I","volume":"108","author":"Creager","year":"2003","journal-title":"Circulation"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000074043.46437.44","article-title":"Elevated Plasma Levels of the Atherogenic Mediator Soluble CD40 Ligand in Diabetic Patients: A Novel Target of Thiazolidinediones","volume":"107","author":"Varo","year":"2003","journal-title":"Circulation"},{"key":"B29","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1160\/TH04-07-0453","article-title":"Prevention of Cardiovascular Disease in Type-2 Diabetes: How to Improve the Clinical Efficacy of Aspirin","volume":"93","author":"Evangelista","year":"2005","journal-title":"Thromb Haemost"},{"key":"B30","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","article-title":"2019 ESC Guidelines on Diabetes, Pre-Diabetes, and Cardiovascular Diseases Developed in Collaboration With the EASD","volume":"41","author":"Cosentino","year":"2020","journal-title":"Eur Heart J"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.pcd.2019.11.004","article-title":"Aspirin in the Primary Prevention of Cardiovascular Disease on Diabetic Patients: Systematic Review and Meta-Analysis","volume":"14","author":"Caldeira","year":"2020","journal-title":"Prim Care Diabetes"},{"key":"B32","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1186\/s12916-019-1428-0","article-title":"Aspirin for the Primary Prevention of Cardiovascular Disease: A Meta-Analysis With a Particular Focus on Subgroups","volume":"17","author":"Gelbenegger","year":"2019","journal-title":"BMC Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1111\/dme.13133","article-title":"Aspirin For the Primary Prevention of Cardiovascular and All-Cause Mortality Events in Diabetes: Updated Meta-Analysis of Randomized Controlled Trials","volume":"34","author":"Kunotsor","year":"2017","journal-title":"Diabetes Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra052717","article-title":"Low-Dose Aspirin for the Prevention of Atherothrombosis","volume":"353","author":"Patrono","year":"2005","journal-title":"N Eng J Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1136\/BMJ.321.7270.1183","article-title":"Risk of Gastrointestinal Haemorrhage With Long Term Use of Aspirin: Meta-Analysis","volume":"321","author":"Derry","year":"2000","journal-title":"BMJ"},{"key":"B36","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/1741-7015-4-22","article-title":"Cardioprotective Aspirin Users and Their Excess Risk of Upper Gastrointestinal Complications","volume":"4","author":"Hern\u00e1ndez-D\u00edaz","year":"2006","journal-title":"BMC Med"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2021.741374\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,4]],"date-time":"2021-09-04T01:38:08Z","timestamp":1630719488000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2021.741374\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,1]]},"references-count":36,"alternative-id":["10.3389\/fendo.2021.741374"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2021.741374","relation":{},"ISSN":["1664-2392"],"issn-type":[{"type":"electronic","value":"1664-2392"}],"subject":[],"published":{"date-parts":[[2021,9,1]]},"article-number":"741374"}}